TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2014

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Robert A Burger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.